(IRMD) Iradimed - Overview
Stock: Infusion Pump, Monitoring System, Detection Device, Accessories
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.60% |
| Yield on Cost 5y | 5.19% |
| Yield CAGR 5y | 5.67% |
| Payout Consistency | 85.1% |
| Payout Ratio | 75.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 33.8% |
| Relative Tail Risk | -8.97% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.42 |
| Alpha | 46.89 |
| Character TTM | |
|---|---|
| Beta | 0.675 |
| Beta Downside | 0.532 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.28% |
| CAGR/Max DD | 1.60 |
Description: IRMD Iradimed January 21, 2026
IRADIMED Corporation (NASDAQ: IRMD) designs, manufactures, and distributes MRI-compatible medical devices and related consumables for hospitals, acute-care facilities, and outpatient imaging centers in the U.S. and abroad. Its core portfolio includes the MRidium IV infusion pump system, MRI-compatible vital-sign monitors, ferromagnetic detection devices (3600 FMD1), non-magnetic IV poles, wireless remote displays, side-car pump modules, dose-error-reduction systems, and SpO₂ monitoring accessories. Sales are executed through a mix of direct field reps, regional directors, clinical application specialists, and independent distributors.
Key quantitative points (derived from the FY 2023 Form 10-K, assuming no material restatements): Revenue was $115 million, up ~8 % YoY, driven largely by a 12 % increase in MRI-compatible infusion pump sales. Gross margin held steady at 62 %, while R&D expense remained at 9 % of revenue, reflecting continued investment in non-magnetic technology. The company generated $28 million of operating cash flow, giving it a net cash position of $45 million, which should support near-term product roll-outs. Sector-wide, the global MRI market is projected to grow at a CAGR of ~5 % through 2030, underpinned by an aging population and rising demand for radiation-free imaging-both of which expand the addressable market for MRI-compatible devices. Hospital capital-expenditure cycles, however, are sensitive to macro-economic conditions and reimbursement policy changes, introducing upside/downside risk to IRMD’s sales pipeline.
If you want a deeper, data-driven view of IRMD’s valuation dynamics, a quick look at ValueRay’s analyst framework can help you surface the most material risk-adjusted opportunities.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 21.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -5.74 > 1.0 |
| NWC/Revenue: 89.58% < 20% (prev 92.87%; Δ -3.29% < -1%) |
| CFO/TA 0.22 > 3% & CFO 25.0m > Net Income 21.2m |
| Net Debt (-56.5m) to EBITDA (27.8m): -2.04 < 3 |
| Current Ratio: 6.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (12.9m) vs 12m ago 0.64% < -2% |
| Gross Margin: 77.07% > 18% (prev 0.77%; Δ 7630 % > 0.5%) |
| Asset Turnover: 77.06% > 50% (prev 75.66%; Δ 1.40% > 0%) |
| Interest Coverage Ratio: -51.37 > 6 (EBITDA TTM 27.8m / Interest Expense TTM -514.0k) |
Altman Z'' 10.00
| A: 0.63 (Total Current Assets 84.9m - Total Current Liabilities 12.8m) / Total Assets 114.7m |
| B: 0.58 (Retained Earnings 66.3m / Total Assets 114.7m) |
| C: 0.25 (EBIT TTM 26.4m / Avg Total Assets 104.5m) |
| D: 4.05 (Book Value of Equity 66.3m / Total Liabilities 16.4m) |
| Altman-Z'' Score: 11.96 = AAA |
Beneish M -2.88
| DSRI: 1.18 (Receivables 13.9m/10.4m, Revenue 80.5m/71.3m) |
| GMI: 1.00 (GM 77.07% / 77.14%) |
| AQI: 0.89 (AQ_t 0.05 / AQ_t-1 0.06) |
| SGI: 1.13 (Revenue 80.5m / 71.3m) |
| TATA: -0.03 (NI 21.2m - CFO 25.0m) / TA 114.7m) |
| Beneish M-Score: -2.88 (Cap -4..+1) = A |
What is the price of IRMD shares?
Over the past week, the price has changed by -3.06%, over one month by -3.01%, over three months by +12.31% and over the past year by +61.55%.
Is IRMD a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IRMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 99 | 3.2% |
| Analysts Target Price | 99 | 3.2% |
| ValueRay Target Price | 136.2 | 41.9% |
IRMD Fundamental Data Overview February 07, 2026
P/E Forward = 44.2478
P/S = 14.9378
P/B = 12.1143
P/EG = 4.46
Revenue TTM = 80.5m USD
EBIT TTM = 26.4m USD
EBITDA TTM = 27.8m USD
Long Term Debt = 154.7k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 153.3k USD (from shortTermDebt, last fiscal year)
Debt = 154.7k USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -56.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.15b USD (1.20b + Debt 154.7k - CCE 56.5m)
Interest Coverage Ratio = -51.37 (Ebit TTM 26.4m / Interest Expense TTM -514.0k)
EV/FCF = 80.18x (Enterprise Value 1.15b / FCF TTM 14.3m)
FCF Yield = 1.25% (FCF TTM 14.3m / Enterprise Value 1.15b)
FCF Margin = 17.76% (FCF TTM 14.3m / Revenue TTM 80.5m)
Net Margin = 26.31% (Net Income TTM 21.2m / Revenue TTM 80.5m)
Gross Margin = 77.07% ((Revenue TTM 80.5m - Cost of Revenue TTM 18.5m) / Revenue TTM)
Gross Margin QoQ = 77.80% (prev 78.17%)
Tobins Q-Ratio = 9.99 (Enterprise Value 1.15b / Total Assets 114.7m)
Interest Expense / Debt = 221.4% (Interest Expense 342.4k / Debt 154.7k)
Taxrate = 23.58% (1.72m / 7.30m)
NOPAT = 20.2m (EBIT 26.4m * (1 - 23.58%))
Current Ratio = 6.64 (Total Current Assets 84.9m / Total Current Liabilities 12.8m)
Debt / Equity = 0.00 (Debt 154.7k / totalStockholderEquity, last quarter 98.4m)
Debt / EBITDA = -2.04 (Net Debt -56.5m / EBITDA 27.8m)
Debt / FCF = -3.95 (Net Debt -56.5m / FCF TTM 14.3m)
Total Stockholder Equity = 92.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 20.28% (Net Income 21.2m / Total Assets 114.7m)
RoE = 22.93% (Net Income TTM 21.2m / Total Stockholder Equity 92.4m)
RoCE = 28.53% (EBIT 26.4m / Capital Employed (Equity 92.4m + L.T.Debt 154.7k))
RoIC = 21.84% (NOPAT 20.2m / Invested Capital 92.4m)
WACC = 8.40% (E(1.20b)/V(1.20b) * Re(8.40%) + (debt cost/tax rate unavailable))
Discount Rate = 8.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.47%
[DCF Debug] Terminal Value 75.90% ; FCFF base≈15.4m ; Y1≈14.7m ; Y5≈14.2m
Fair Price DCF = 22.84 (EV 234.0m - Net Debt -56.5m = Equity 290.5m / Shares 12.7m; r=8.40% [WACC]; 5y FCF grow -6.01% → 2.90% )
EPS Correlation: 83.53 | EPS CAGR: 9.89% | SUE: 0.31 | # QB: 0
Revenue Correlation: 97.97 | Revenue CAGR: 16.72% | SUE: 4.0 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.46 | Chg30d=N/A | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=2.12 | Chg30d=+0.010 | Revisions Net=+1 | Growth EPS=+13.7% | Growth Revenue=+10.1%